Paradromics Receives FDA Approval to Expand Nationwide Connexus Brain-Computer Interface Study
Paradromics has received FDA approval to expand recruitment for its Connexus® Brain-Computer Interface (BCI) clinical study to additional sites across the United States. The expansion is intended to increase access to the study for people with severe communication impairments.
The revised study protocol removes the previous requirement that participants live within a four-hour drive of a clinical site. Eligible candidates from across the continental United States can now be considered, although they must still travel for screening, study visits and follow-up assessments.
The Connexus BCI is a fully implantable, wireless system that records electrical activity from individual neurons in the brain. It uses a high-density microelectrode array to capture neural signals and transmit them wirelessly through an implanted chest receiver to an external computer for processing.
The technology is designed to translate intended and imagined speech into text and synthesised speech, while also enabling computer control for people with severe motor impairments.
The Connect-One Early Feasibility Study is being conducted at three academic medical centres: UC Davis Health, Mass General Brigham and University of Michigan Health.
In September 2026, the first participant in the study demonstrated real-time communication using the system, including generating words, answering questions and communicating with family members through a phone call.
The study will evaluate the long-term safety and performance of the technology and its potential to restore communication for people with severe speech and motor impairments. Connexus remains an investigational device and is not approved for commercial use.